Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments.
J Hum Virol
; 5(1): 17-23, 2002.
Article
en En
| MEDLINE
| ID: mdl-12352264
The antigenic diversity, rapid genetic integration into host cell DNA, and immune evasion tactics of human immunodeficiency virus type 1 (HIV-1) create formidable obstacles to the development of an effective vaccine against it. In spite of this, the advent of conformationally constrained HIV-1 Env and gp120 immunogens has made it feasible to formulate HIV-1 vaccines that induce broadly cross-reactive neutralizing antibodies and afford protection through humoral mechanisms. This paper reviews recent advances made by the authors toward the development of an HIV-1 vaccine that elicits such antibodies in both the mucosal and systemic immune compartments.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Diseño de Fármacos
/
Anticuerpos Anti-VIH
/
Infecciones por VIH
/
VIH-1
/
Vacunas contra el SIDA
/
Inmunidad Mucosa
Límite:
Humans
Idioma:
En
Revista:
J Hum Virol
Asunto de la revista:
VIROLOGIA
Año:
2002
Tipo del documento:
Article
País de afiliación:
Estados Unidos
Pais de publicación:
Estados Unidos